These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9723248)

  • 1. Evaluation of the safety and tolerability of Neoral and Sandimmune: a meta-analysis.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Aug; 30(5):1697-700. PubMed ID: 9723248
    [No Abstract]   [Full Text] [Related]  

  • 2. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoral use in the cardiac transplant recipient.
    Valantine H
    Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
    Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
    Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.
    Lodge JP; Pollard SG
    Transplant Proc; 1997; 29(1-2):272-3. PubMed ID: 9122991
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.
    Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA
    Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplant Proc; 1996 Aug; 28(4):2183-6. PubMed ID: 8769194
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
    Abendroth D; Buchholz B; Land W; May G; Wiesel M; Färber L; Korn A; Maibücher A
    Transplant Proc; 1997; 29(1-2):275-6. PubMed ID: 9122993
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships.
    Mueller EA; Niese D; Mellein B
    Transplant Proc; 1998 Aug; 30(5):1694-6. PubMed ID: 9723247
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoral conversion study: shift from Sandimmune classic formulation to Sandimmune Neoral in heart and lung transplant patients.
    Svendsen U; Larsen K; Allermand H; Thayssen P; Jensen S; Pettersson G
    Transplant Proc; 1995 Dec; 27(6):3477. PubMed ID: 8540057
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced acute rejection and side effects with neoral in liver transplantation.
    Tisone G; Vennarecci G; Pisani F; Baiocchi L; Mercadante E; Orlando G; Anselmo A; Casciani CU
    Transplant Proc; 1998 Jun; 30(4):1430-1. PubMed ID: 9636579
    [No Abstract]   [Full Text] [Related]  

  • 12. Early use and oral absorption of cyclosporine neoral after liver transplantation.
    Kattner A; Ringe B; Haller GW; Kirchner G; Sewing KF; Winkler M
    Transplant Proc; 1998 Jun; 30(4):1422-3. PubMed ID: 9636576
    [No Abstract]   [Full Text] [Related]  

  • 13. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
    Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
    Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation.
    Maccherini M; Bernazzali S; Diciolla F; Giunti G; Bizzarri F; Lisi GF; Davoli G; Biagioli B; Giomarelli PP; Simeone F; Caciorgna M; Marchetti L; Pula G; Sani G; Toscano M
    Transplant Proc; 1998 Aug; 30(5):1904-5. PubMed ID: 9723327
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.
    Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
    Transplant Proc; 1998 Aug; 30(5):1830-2. PubMed ID: 9723299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from Sandimmune to Neoral in stable liver graft recipients.
    Pollard SG; Lodge JP
    Transplant Proc; 1996 Aug; 28(4):2244-6. PubMed ID: 8769213
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group.
    Brennan DC; Barbeito R; Burke J; Brayman K; Greenstein S; Chang T
    Kidney Int; 1999 Aug; 56(2):685-91. PubMed ID: 10432409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients.
    Gaston R; Alloway RR; Gaber AO; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; First MR
    Transplant Proc; 1999; 31(1-2):326-7. PubMed ID: 10083128
    [No Abstract]   [Full Text] [Related]  

  • 19. An open randomized parallel group study to compare Sandimmune Neoral with Sandimmune soft gelatin capsule in stable renal transplant patients.
    Park K; Koh YB; Kwak JY; Kim SJ; Yoon YS; Kang CM; Kim YS
    Transplant Proc; 1996 Jun; 28(3):1202-3. PubMed ID: 8658627
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.
    Korn A; Färber L; Maibücher A; Buchholz B; Offermann G
    Transplant Proc; 1997 Nov; 29(7):2945-7. PubMed ID: 9365623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.